Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

Journal of the American Society of Nephrology

Volumn 19, Issue 6, 2008, Pages 1225-1232

  Hamdy, Ahmed Farouk ^a   Bakr, Mohamed A ^a   Ghoneim, Mohamed A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; CABIN1 PROTEIN, HUMAN; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ANEMIA; ARTICLE; BODY WEIGHT; BONE NECROSIS; CHRONIC DIARRHEA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; FIBROSING ALVEOLITIS; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HERNIORRHAPHY; HERPES ZOSTER; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCELE; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; OVARY CYST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SKIN ULCER; SURVIVAL; THROMBOCYTOPENIA; TUBERCULOSIS; URINARY TRACT FISTULA; WOUND COMPLICATION; CONTROLLED STUDY; KIDNEY TRANSPLANTATION; LIVING DONOR; METHODOLOGY; TIME;

CALCINEURIN; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS;

EID: 48049104898     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007091001     Document Type: Article

References (32)

1. Myers BD: Cyclosporine nephrotoxicity. Kidney Int 30: 964-974, 1986
2. Remuzzi G, Bertani T: Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 13: 261-272, 1989
3. Bennett WM, Houghton DC, Buss WC: Cyclosporine-induced renal dysfunction: Correlations between cellular events and whole kidney function. J Am Soc Nephrol 1: 1212-1219, 1991
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
5. Ducloux D, Fournier V, Bresson-Vautrin C, Rebibou JM, Billerey C, Saint-Hiller Y, Chalpoin JM: Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report. Transplantation 65: 1504-1506, 1998
6. Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X, Ramos R, Coll O, Alsina J, Grynio JM: Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 66: 1727-1731, 1998
7. Keunecke C, Rothenpieler U, Zanker B, Schneeberger H, Miner WD, Theodorakis J, Stangl M, Land W: Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients. Transplant Proc 32[Suppl]: S6-S8, 2000
8. Schrama YC, Joles JA, van Tol A, Boer P, Koomans HA, Hene RJ: Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 69: 376-383, 2000
9. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71: 1282-1287, 2001
10. Tran HT, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss HJR, Kirkman RL, Milford EL: Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903-1909, 2000
11. Groth CG, Backman L, Morales JM: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine: Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042, 1999
12. Kreis H, Cisterne JM, Land W: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000
13. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastorianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: A prospective randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002
14. Hamdy AF, El-Agroudy A, Bakr MA, Mostafa A, El-baz M, El-Shahawy M, Ghoneim MA: Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 5: 2531-2538, 2005
15. Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML, Leichtman AB: Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 6: 1111-1131, 2006
16. Flechner S, Goldfarb D, Solez K, Modlin C, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick A, Cook DJ: Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 83: 883-892, 2007
17. Diekmann F, Gutierrez-Dalmau A, Lopez S, Cofan F, Esforzado N, Ricart MJ, Rossich E, Saval N, Torregrosa J, Oppenheimer F, Campistol JM: Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 22: 2316-2321, 2007
18. Stephany B, Augustine J, Krishnamurthi V, Goldfarb D, Flechner S, Braun W, Hricik D, Dennis V, Poggio E: Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 82: 368-374, 2006
19. Hricik DE, Anton HA, Knauss TC, Rodriguez V, Seaman D, Siegel C, Valente J, Schulak JA: Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus and corticosteroids. Transplantation 74: 189-193, 2002
20. Lo A, Egidi MF, Gaber L, Amiri H, Vera S, Nezakatgoo N, Gaber O: Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 77: 1228-1235, 2004
21. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6: 514-522, 2006
22. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 73: 732-736, 2002
23. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 39[Suppl 1]: S1-S266, 2002
24. Isoniemi HM, Krogerus I, Von Willebrand E, Taskinen E, Ahonen J, Hayry P: Histopathological findings in well-functioning, long term renal allografts. Kidney Int 41: 155-160, 1992
25. El-Agroudy A, Refaie A, Moussa O, Ghoneim M: Tuberculosis in Egyptian kidney transplant recipients: Study of clinical course and outcome. J Nephrol 16: 404-411, 2003
26. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M: Rapamycin blocks tumour progression: Unlinking immunosuppression from antitumour efficacy. Transplantation 73: 1565-1572, 2002
27. Wilson DH, Book B, Brunet M, Engelmayer J, Gaulier JM, Luthe H, Marquet P, Moscato D, Mosso R, Oellerich M, Pescovitz M, Ramanathan L, Schmid R, Stickle D, Sarkozi L, Wallemacq P: Multicenter evaluation of an immunoassay for the measurement of sirolimus on the Abbott IMx analyzer. Transplantation 78[Suppl 1]: 477-478, 2004
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560-2572, 2003
29. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 1227-1236, 1976
30. Racusen L, Solez K, Colvin R, Bonsib SM, Castro MC, Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
31. Kaplan EL, Meier P: Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958
32. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc 135: 185-207, 1972